PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) CEO Dr. Michael Myers, who shares the company's notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet medical needs for those with Netherton Syndrome (NS), a rare and sometimes fatal skin disease for which there is currently no approved ...